Red Light Therapy for Fibromyalgia: Evidence & Benefits
TL;DR
- Red light therapy has documented effects on the core mechanisms driving fibromyalgia: mitochondrial dysfunction, oxidative stress, neuroinflammation, small-fibre neuropathy, and central sensitisation. These are not incidental overlaps but direct therapeutic targets.
- A 2023 NHS feasibility trial using whole-body photobiomodulation for fibromyalgia found significant improvements across pain intensity, pain interference, fatigue, sleep, anxiety, depression, stiffness, and cognitive function after an 18-session protocol. 64% of participants reduced or stopped opioid medications by the end of the trial.
- A 2019 systematic review and meta-analysis found that photobiomodulation significantly reduced Fibromyalgia Impact Questionnaire scores, tender point count, pain, fatigue, and stiffness across nine randomised controlled trials.
- Fibromyalgia involves widespread pain across the whole body, which makes whole-body photobiomodulation a particularly well-suited treatment approach compared to localised panel sessions targeting individual areas.
- Red light therapy is not a cure for fibromyalgia and should be used alongside other evidence-based management strategies. Results build with consistent use over weeks and months rather than individual sessions.
Fibromyalgia affects an estimated 2 to 4% of Australians and is characterised by widespread chronic pain, fatigue, sleep disturbance, cognitive impairment, and significant impacts on daily functioning and quality of life. Despite being the second most common rheumatological condition globally, effective treatment options remain limited. Standard pharmaceutical management often produces modest benefits alongside significant side effects, and many people with fibromyalgia find themselves cycling through treatments without sustainable relief.
Red light therapy is emerging as one of the more promising complementary approaches for fibromyalgia, with a growing clinical evidence base that directly addresses several of the biological mechanisms driving the condition. This article works through what the research shows, why red light therapy is particularly well suited to fibromyalgia, and how to approach it practically.
What Is Fibromyalgia and Why Is It Difficult to Treat?
Fibromyalgia is a multisystem disorder involving widespread musculoskeletal pain, fatigue, non-restorative sleep, cognitive difficulties often called fibro fog, and frequent comorbidities including anxiety, depression, irritable bowel syndrome, and headaches. The condition is characterised by central sensitisation, where the central nervous system processes pain with amplified sensitivity, making the body's pain response disproportionate to any identifiable tissue injury.
At the cellular level, fibromyalgia involves mitochondrial dysfunction with reduced ATP production, elevated reactive oxygen species, impaired oxygen delivery to muscles due to reduced capillary density and function, and evidence of small-fibre peripheral neuropathy affecting the fine nerve fibres that transmit pain and autonomic signals. These biological mechanisms explain the widespread nature of fibromyalgia symptoms and point directly to where photobiomodulation therapy exerts its effects.
The challenge of treating fibromyalgia is that its multifactorial nature means single-target treatments rarely produce comprehensive relief. Medications that address one pathway, such as pain modulation, often fail to improve sleep, fatigue, or cognitive function. This is where whole-body photobiomodulation, which acts simultaneously across multiple biological pathways, is showing particular promise.
How Red Light Therapy Works for Fibromyalgia
Mitochondrial Dysfunction and ATP Production
Mitochondrial dysfunction is a well-documented feature of fibromyalgia, with reduced ATP synthesis contributing to muscle fatigue, post-exertional malaise, and impaired cellular repair. Red and near-infrared light targets cytochrome c oxidase in the mitochondrial respiratory chain, the primary photoacceptor in photobiomodulation, increasing electron transport efficiency and ATP output. As documented in a foundational review by Hamblin (2018), this mitochondrial stimulation reduces oxidative stress and increases the availability of cellular energy for repair and function. For fibromyalgia patients where mitochondrial dysfunction is a central pathological feature, this mechanism directly addresses one of the root drivers of fatigue and widespread muscle pain.
Oxidative Stress and Inflammation
Elevated reactive oxygen species and chronic low-grade inflammation are consistently documented in fibromyalgia and contribute to the central sensitisation that amplifies pain signals. A 2019 meta-analysis by Yeh et al. published in Pain Physician analysed nine randomised controlled trials of photobiomodulation for fibromyalgia and found significant reductions in Fibromyalgia Impact Questionnaire (FIQ) scores, tender point count, pain, fatigue, and stiffness. The researchers attributed these effects to photobiomodulation's documented ability to reduce pro-inflammatory cytokines and oxidative stress markers at the tissue level.
Small-Fibre Neuropathy
Emerging research has identified small-fibre neuropathy as a feature of fibromyalgia in a significant subset of patients. Small-fibre nerves transmit pain signals and regulate autonomic functions including circulation, sweating, and heart rate. Damage to these fibres contributes to the burning pain, skin hypersensitivity, and autonomic symptoms common in fibromyalgia.
Photobiomodulation has documented effects on peripheral nerve regeneration and small-fibre function, as reviewed in the 2023 whole-body PBMT feasibility trial published in Behavioural Sciences, which noted that the widespread nature of fibromyalgia pain including its small-fibre neuropathy component makes the whole-body treatment approach particularly advantageous compared to localised panel therapy targeting individual painful areas.
Sleep, Fatigue, and Cognitive Function
Non-restorative sleep and cognitive impairment, collectively described as fibro fog, are among the most disabling features of fibromyalgia and are poorly addressed by most pharmacological treatments. Red light therapy's effects on melatonin production, circadian rhythm regulation, and neuroinflammation provide multiple pathways through which it may support sleep quality and cognitive function in fibromyalgia.
The 2023 NHS feasibility trial specifically tracked sleep using the validated Jenkins Sleep Questionnaire and found that all participants who showed sleep improvement achieved improvements exceeding 20%, with an overall mean improvement of 33.6%. Cognitive function measured by the Stroop Test also showed improvements post-treatment, consistent with the broader anti-inflammatory and mitochondrial effects of photobiomodulation on brain function.
The Clinical Evidence
2019 Systematic Review and Meta-Analysis (Yeh et al.)
The most comprehensive evidence synthesis for photobiomodulation in fibromyalgia is the 2019 systematic review and meta-analysis by Yeh et al. published in Pain Physician, which analysed nine randomised controlled trials involving fibromyalgia patients receiving low-level laser therapy or LED photobiomodulation. The meta-analysis found significant improvements in Fibromyalgia Impact Questionnaire total scores, number of tender points, pain intensity, fatigue, and stiffness compared to control groups. The researchers concluded that photobiomodulation is an effective intervention for fibromyalgia symptom management with a favourable safety profile and no significant adverse events across the included trials.
2023 NHS Whole-Body PBMT Feasibility Trial (Fitzmaurice et al.)
The most recent and clinically significant study is the 2023 whole-body photobiomodulation feasibility trial conducted at Sandwell and West Birmingham NHS Trust, published in Behavioural Sciences. The trial enrolled 21 fibromyalgia patients with clinician-confirmed diagnoses, delivering 18 sessions of whole-body photobiomodulation at 660nm and 850nm over approximately six weeks, with a 24-week follow-up.
The results across all measured outcome domains were striking. Fibromyalgia Impact Questionnaire scores improved by an average of 24.44 points, a statistically significant improvement that persisted, albeit partially, at the 24-week follow-up. Pain intensity dropped from an average of 7.08 out of 10 to 3.93 out of 10. Pain interference scores improved significantly. Sleep quality improved in 68.4% of participants, all with improvements exceeding 20%. Anxiety scores reduced by 24.8% and depression scores by 34.3%. Stiffness and cognitive function both showed clinically significant improvements.
Critically, 64.3% of participants reduced or stopped opioid-based medications by the end of the six-week trial. This included reductions in codeine, tramadol, morphine, and transdermal opioid patches. Two participants also stopped duloxetine, a serotonin-norepinephrine reuptake inhibitor commonly used for fibromyalgia pain, including one participant who had been taking the maximum dose of 120mg. These medication reductions occurred without clinical guidance to do so, suggesting participants experienced sufficient pain relief to self-initiate dose reductions.
The researchers specifically noted that the whole-body approach was advantageous for fibromyalgia compared to localised treatment because fibromyalgia pain is widespread and diffuse, meaning targeting individual painful areas fails to address the condition's systemic nature. Whole-body photobiomodulation treats all affected areas simultaneously and provides sufficient brain penetration to address the central mechanisms driving fibro fog, sleep disturbance, and mood symptoms.
Why Whole-Body Treatment Is Particularly Relevant for Fibromyalgia
Most red light therapy content focuses on localised panel use, where a device is positioned over a specific body part for targeted treatment. For conditions with localised pathology, such as knee osteoarthritis or a shoulder injury, this approach is well suited. Fibromyalgia is different.
Fibromyalgia pain is typically widespread, affecting multiple muscle groups, joints, and soft tissue areas simultaneously. The 18 tender points used in fibromyalgia diagnosis span the neck, shoulders, chest, hips, knees, and elbows bilaterally. Fatigue, fibro fog, sleep disturbance, and mood effects are systemic rather than localised. This is why the NHS trial specifically chose a whole-body treatment modality and noted the advantage of whole-body coverage for this population.
For at-home use, full-body mat devices provide the closest equivalent to the whole-body approach, treating the entire body surface in each session rather than requiring sequential repositioning across multiple painful areas. For people whose symptoms fluctuate across different body regions from day to day, the comprehensive coverage of a mat or full-body panel also removes the need to predict which areas will need treatment before the session begins.
Practical Protocol for Fibromyalgia
Session frequency and Duration
The NHS feasibility trial used three sessions per week for six weeks, 18 sessions total, with session duration progressing from 6 minutes in the first session to 20 minutes from session three onwards. This graduated approach allowed the body to adjust to treatment and minimised any initial response reactions. For at-home use, the same three-sessions-per-week protocol over a minimum of six to eight weeks is the most evidence-aligned approach.
Fibromyalgia is a condition where gradual uptitration of session duration makes practical sense. Starting at 10 minutes and building to 20 minutes over the first two weeks mirrors the clinical protocol and allows monitoring of any initial responses, which may include temporary increases in pain or fatigue in the first one to two sessions before the anti-inflammatory and cellular energy effects establish.
Timing of Sessions
For fibromyalgia, session timing should be guided by individual symptom patterns. Morning sessions may benefit people whose primary goal is energy and cognitive function, supporting the day ahead. Evening sessions, ending at least an hour before sleep, may benefit people whose primary goals are sleep quality and pain reduction overnight. Many fibromyalgia patients find consistent timing at the same time each day easier to maintain, which also supports the circadian regulation effects of regular light exposure.
Managing Post-Treatment Responses
Some fibromyalgia patients report a temporary increase in symptoms in the first one to three sessions of red light therapy. This is a known response in central sensitisation conditions where any new stimulus can initially trigger a flare before the anti-inflammatory and cellular effects establish. Starting with shorter sessions, 10 minutes rather than 20, and gradually increasing is the most practical approach to minimising this. If a significant flare occurs, reducing session time and returning to baseline before progressing again is preferable to stopping treatment entirely.
StreamShop Devices for Fibromyalgia
Given that fibromyalgia involves widespread pain across the whole body, devices that provide the broadest coverage are most relevant. The following StreamShop options are matched to the treatment approach supported by the clinical evidence.
Red Light Therapy Mat
StreamShop's red light therapy mat provides full-body coverage in a single session, making it the closest at-home equivalent to the whole-body photobiomodulation approach used in the NHS feasibility trial. For fibromyalgia patients where pain and symptoms shift across body regions from day to day, full-body coverage removes the need to target individual areas and ensures all affected tissue receives treatment simultaneously. This is the most practical and accessible full-body device for the widespread, diffuse nature of fibromyalgia.
Laser Mat With 1064nm
For the most comprehensive full-body treatment available, StreamShop's red light therapy laser mat with 1064nm combines LED and laser technology across six wavelengths including 630nm, 660nm, 830nm, 850nm, 940nm, and 1064nm at 110 mW/cm² across a 1.8m x 80cm treatment surface. The inclusion of 160 x 1064nm laser diodes alongside 560 x 1064nm LEDs provides the deepest tissue penetration available in a mat format, making it particularly relevant for fibromyalgia patients with significant small-fibre neuropathy components or deep tissue involvement. This is the most advanced full-body option for comprehensive systemic treatment.
Red Light Therapy Laser Bed
StreamShop's red light therapy laser bed uses 1064nm VCSEL laser technology for full-body treatment at the deepest-penetrating wavelength available. For fibromyalgia patients who have not responded adequately to LED-based approaches or who have complex systemic presentations, the laser bed provides the most intensive full-body photobiomodulation experience in the StreamShop range.
Red Light Therapy Belt
StreamShop's red light therapy belt at $149.99 is the most accessible entry point for fibromyalgia and is well suited to targeting the areas of most intense pain on a given day. The 126cm x 18cm belt wraps around the lower back, abdomen, hips, thighs, or shoulders delivering 660nm and 850nm at 120 mW/cm² across 105 dual chip LEDs. Its power bank compatibility allows passive wearable treatment throughout the day without being tethered to a wall, which is practical for people whose fatigue limits the time and energy available for dedicated sessions.
Joint Wrap and Leg Wrap for Localised Flares
For targeted relief during fibromyalgia flares affecting specific joints or lower limb areas, StreamShop's red light therapy joint wrap and red light therapy leg wrap provide wearable contact devices for direct localised treatment. The joint wrap covers knees, shoulders, ankles, elbows, and wrists. The leg wrap covers both legs from feet to knee in a single session. These are most useful as supplements to whole-body or belt treatment, used when specific areas are particularly symptomatic between full-body sessions.
Important Considerations for Fibromyalgia
- Red light therapy is a complementary approach and should be used alongside, not instead of, evidence-based fibromyalgia management including graded exercise, pain education, sleep hygiene, and appropriate medical care.
- Do not reduce or stop medications without guidance from your healthcare provider. While the NHS trial documented voluntary medication reductions in some participants, any medication changes should be discussed with your prescriber.
- Fibromyalgia flares are unpredictable and may affect your ability to maintain treatment frequency. Flexibility in session scheduling is more sustainable than rigid protocols that become impossible to maintain during flare periods.
- Results build cumulatively over weeks and months. The 24-week follow-up in the NHS trial showed that while FIQR scores partially increased between weeks 6 and 24, they remained significantly improved from baseline, suggesting that periodic ongoing use maintains benefit.
- People with photosensitive conditions or taking photosensitising medications should consult their healthcare provider before starting.
Frequently Asked Questions
Does red light therapy help fibromyalgia?
The evidence supports red light therapy as a beneficial complementary approach for fibromyalgia. A 2019 meta-analysis of nine randomised controlled trials found significant improvements in pain, fatigue, stiffness, and Fibromyalgia Impact Questionnaire scores. A 2023 NHS feasibility trial using whole-body photobiomodulation documented improvements across all measured fibromyalgia symptom domains including pain, sleep, fatigue, anxiety, depression, and cognitive function, with 64% of participants reducing or stopping opioid medications.
How long does red light therapy take to work for fibromyalgia?
Fibromyalgia is a chronic condition and results build with consistent use over weeks rather than sessions. The NHS trial used 18 sessions over six weeks before assessing outcomes. Most people begin noticing changes in energy and sleep quality within the first two to three weeks, with more substantial pain and fatigue improvements emerging from weeks four to six of consistent treatment. A minimum of eight weeks of regular use is recommended before assessing overall effectiveness.
Is whole-body red light therapy better for fibromyalgia than a panel?
The clinical evidence specifically highlights the advantage of whole-body photobiomodulation for fibromyalgia because the condition involves widespread pain across multiple body regions simultaneously. Localised panel treatment requires sequential repositioning to cover all affected areas, which is time-consuming and may miss symptomatic regions. Full-body coverage treats all affected tissue simultaneously and provides sufficient light delivery to support the central nervous system effects relevant to fibro fog, sleep, and mood.
Can red light therapy help fibro fog?
The 2023 NHS trial specifically measured cognitive function using the Stroop Test and found improvements post-treatment. Self-reported memory problems showed a mean improvement of 33.2% following the treatment course. The mechanisms thought to underlie this include reduced neuroinflammation, improved mitochondrial function in brain cells, and better sleep quality reducing cognitive fatigue. Fibro fog improvements typically follow pain and sleep improvements rather than appearing first.
How often should I use red light therapy for fibromyalgia?
Three sessions per week is the protocol used in the NHS feasibility trial and is the most evidence-aligned frequency for fibromyalgia. Some participants in that trial expressed a preference for daily sessions, suggesting that more frequent use may be well tolerated. Starting at three times per week and adjusting based on response and tolerance is the most practical approach. Sessions of 15 to 20 minutes for full-body devices are appropriate once the initial weeks of graduated sessions are completed.
Is red light therapy safe for fibromyalgia?
The 2019 meta-analysis and 2023 NHS trial both documented no significant adverse events. Red light therapy is non-invasive, does not use ionising radiation, and does not generate significant heat at therapeutic settings. The main caution for fibromyalgia specifically is that some people with central sensitisation may experience a temporary symptom flare in the first one to three sessions. Graduated session duration, starting shorter and building up, minimises this response.